{
    "2021-03-12": [
        [
            {
                "time": "",
                "original_text": "复星医药(02196)拟向激励对象授予限制性股票不超过240.72万股",
                "features": {
                    "keywords": [
                        "复星医药",
                        "限制性股票",
                        "激励计划"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "复星医药：发布2021年限制性股票激励计划",
                "features": {
                    "keywords": [
                        "复星医药",
                        "2021年",
                        "限制性股票",
                        "激励计划"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "复星医药(600196.SH)拟授出不超过240.72万股A股限制性股票",
                "features": {
                    "keywords": [
                        "复星医药",
                        "A股",
                        "限制性股票",
                        "激励计划"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "复星医药(600196.SH)拟推不超过240.72万股限制性股票激励计划",
                "features": {
                    "keywords": [
                        "复星医药",
                        "限制性股票",
                        "激励计划"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "【异动股】复星医药(02196-HK)跌3.11%",
                "features": {
                    "keywords": [
                        "复星医药",
                        "异动股",
                        "下跌"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2022-03-12",
                "original_text": "智通港股通持股分析|3月12日",
                "features": {
                    "keywords": [
                        "智通",
                        "港股通",
                        "持股分析"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "辉瑞疫苗无症状感染保护力达94%；GSK/Vir中和抗体降低住院/死亡风险85%",
                "features": {
                    "keywords": [
                        "辉瑞疫苗",
                        "无症状感染",
                        "保护力",
                        "GSK/Vir",
                        "中和抗体",
                        "住院",
                        "死亡风险"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}